Delisting riskPopularity #4,715
MSLE · NASDAQ · Biotechnology

Satellos Bioscience (MSLE)

Developing SAT-3247, an oral muscle-repair therapy for Duchenne muscular dystrophy.

$9.02
After hours+0.02 (+0.20%)
At close$9.00(−1.96%)